Lmwh Is the Dominant Heparin Product Market in Europe and Is Expected to Reach Usd 3.14 Billion in 2022

Ultra low molecular weight heparin (ULMWHs) Market, low molecular weight heparin (LMWHs) Market, unfractionated heparin Market, anticoagulants Market.According to a new market report published by Transparency Market Research Heparin Market - Europe Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2022”, the Europe heparin market was valued at USD 2,004.5 million in 2013 and is expected to grow at a CAGR of 5.2% from 2014 to 2022, to reach an estimated value of USD 3,148.0 million in 2022.

Browse the full Heparin Market (Unfractionated Heparin, Low Molecular Weight Heparin & Ultra Low Molecular Weight Heparin) - Europe Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2022 report at http://www.transparencymarketresearch.com/europe-heparin-market.html

Heparin is a highly sulfated glycosaminoglycan sourced from animals, and used as an anticoagulant therapy in patients with blood clots and those undergoing surgery and dialysis. Heparin is generally available as an injection which need to be administered in presence of a healthcare practitioner. Its dosage depends on the medical condition of the patient, drug response and type of heparin. There are three types of heparin available in the European market namely unfractionated heparin, low molecular weight heparin (LMWH) and ultra-low molecular weight heparin (ULMWH). Low molecular weight heparin is the majorly used heparin type in Europe owing to its added advantage over unfractionated heparin. Low molecular weight heparins such as enoxaparin, dalteparin, tinzaparin and certoparin are the majorly sold heparin drugs in Europe.


Unfractionated heparin is mainly used in hospitals and owing to its narrow therapeutic window and the possible risk of bleeding. Although, the effect of unfractionated heparin can be reversed using protamine sulphate, its use is diminishing owing to higher risk of osteopenia and thrombocytopenia. Therefore, researchers...